Board of Directors

Anders Härfstrand
Anders Härfstrand
Chairman of the Board since May 2020, and member of the Board since September 2019.

Born: 1956
Share holdings:

Education: MD and Ph.D from Karolinska Institutet in Stockholm.

Previous experience: Director of Karolinska Development AB from 2017 to 2019 and as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. (now ADAMA); President and Chief Executive Officer of Humabs BioMed SA; and Chief Executive Officer of Nitec Pharma AG (now Horizon Pharmaceuticals). He has also served in various executive roles at Serono, Pfizer and Pharmacia. He has a significant operational global experience of the pharmaceutical industry especially from the US, Japan and Europe.

Other assignments: Chairman of Härfstrand Consulting AG and board member of Prothena Inc.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Hege Hellström
Hege Hellström
Member of the Board since September 2019.

Born: 1965
Share holdings:

Education: B.Sc., Medical Laboratory Scientist, 1985, Oslo Metropolitan University, Norway

Previous experience: Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.

Other assignments: Founder and manager of Belnor BVBA, a consultancy and investment company. She is also a non-executive Board member at Camurus AB (CAMX.ST), a Swedish biotech company, and Advicenne (Euronext: ADVIC), a French pharmaceutical company.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Sven Rohmann
Sven Rohmann
Member of the Board since March 2019.

Born: 1962
Share holdings: 230,630 shares.

Education: MD Johannes Gutenberg University, PhD Erasmus University and MBA European Business School and Kellogg’s University.

Previous experience: CMO for Immudyne Inc, CEO of Adiuvo Investments SA, General Manager Europe for healthcare venture fund Burrill & Co, Vice President Biotec Pharmacon ASA, venture capital fund manager for Novartis Pharma AG, Managing Partner for Nextech Venture, Switzerland, CEO of BioVision AG, CEO of Ganymed Pharmaceuticals AG, and globally responsible for oncology for Merck Serono.

Other assignments: Chairman of Helix Biopharma Corp., ImVision GmbH & Inc. Advisor and Chief Business Development Officer to Oryx GmbH (translational medicine) and Center for Molecular Medicine, KI and TCER AB.

Not independent in relation to Oasmia and the company management, independent in relation to major shareholders of the company

Birgit Stattin Norinder
Birgit Stattin Norinder
Member of the Board since May 2020.

Born: 1948
Share holdings:

Education: M.Sc in Pharmacy from Uppsala University

Previous experience: Extensive experience from international pharmaceutical and biotechnology companies in Sweden, USA and United Kingdom. Amongst many positions she has served as CEO and Chairman of Profilix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit has also held several board and chairman positions of European biotechnology companies.

Other assignments: Member of the Board of AddLife AB, Hansa Biopharma AB and Jettesta AB.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Peter Zonabend
Peter Zonabend
Member of the Board since March 2019.

Born: 1980
Share holdings: 500,000 shares. Manages 79,917 shares by proxy.

Education: LL.M from Stockholm University, EMLE from Erasmus School of Law, Bsc in Business and Economics from Stockholm University and DU EAED from Aix Marseille Université.

Previous experience: CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren.

Other assignments: Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB. CEO Arwidsro, board assignment within Arwidsro.

Independent in relation to Oasmia and company management, not independent of major shareholders in the company.